Stock Market & Financial Investment News

United Therapeutics price target raised to $75 from $65 at ArgusArgus increased its price target on United Therapeutics after the company reported higher than expected Q4 EPS. The firm continues to believe that the company will generate strong long-term growth, and it maintains a Buy rating.